Literature DB >> 17892496

Glutamine and interleukin-1beta interact at the level of Sp1 and nuclear factor-kappaB to regulate argininosuccinate synthetase gene expression.

Carole Brasse-Lagnel1, Alain Lavoinne, David Loeber, Alain Fairand, Christine Bôle-Feysot, Nicolas Deniel, Annie Husson.   

Abstract

We previously demonstrated that the expression of the argininosuccinate synthetase (ASS) gene, a key step in nitric oxide production, is stimulated either by interleukin-1beta[Brasse-Lagnel et al. (2005) Biochimie 87, 403-9] or by glutamine in Caco-2 cells [Brasse-Lagnel et al. (2003) J. Biol. Chem. 278, 52504-10], through the activation of transcription factors nuclear factor-kappaB and Sp1, respectively. In these cells, the fact that glutamine stimulated the expression of a gene induced by pro-inflammatory factors appeared paradoxical as the amino acid is known to exert anti-inflammatory properties in intestinal cells. We therefore investigated the effect of simultaneous addition of both glutamine and interleukin-1beta on ASS gene expression in Caco-2 cells. In the presence of both compounds for 4 h, the increases in ASS activity, protein amount and mRNA level were almost totally inhibited, implying a reciprocal inhibition between the amino acid and the cytokine. The inhibition was exerted at the level of the transcription factors Sp1 and nuclear-kappaB: (a) interleukin-1beta inhibited the glutamine-stimulated DNA-binding of Sp1, which might be related to a decrease of its glutamine-induced O-glycosylation, and (b) glutamine induced per se a decrease in the amount of nuclear p65 protein without affecting the stimulating effect of interleukin-1beta on nuclear factor-kappaB, which might be related to the metabolism of glutamine into glutamate. The present results constitute the first demonstration of a reciprocal inhibition between the effects of an amino acid and a cytokine on gene expression, and provide a molecular basis for the protective role of glutamine against inflammation in the intestine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17892496     DOI: 10.1111/j.1742-4658.2007.06047.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  13 in total

1.  Glutamine activates peroxisome proliferator-activated receptor-γ in intestinal epithelial cells via 15-S-HETE and 13-OXO-ODE: a novel mechanism.

Authors:  Kechen Ban; Julie M Sprunt; Stephanie Martin; Peiying Yang; Rosemary A Kozar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-07-07       Impact factor: 4.052

2.  Anoikis of colon carcinoma cells triggered by β-catenin loss can be enhanced by tumor necrosis factor receptor 1 antagonists.

Authors:  B H Yoo; O Masson; Y Li; I A Khan; P S Gowda; K V Rosen
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

3.  Blockade of Glutamine Synthetase Enhances Inflammatory Response in Microglial Cells.

Authors:  Erika M Palmieri; Alessio Menga; Aurore Lebrun; Douglas C Hooper; D Allan Butterfield; Massimiliano Mazzone; Alessandra Castegna
Journal:  Antioxid Redox Signal       Date:  2016-11-02       Impact factor: 8.401

4.  Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4.

Authors:  Wen-Bin Tsai; Isamu Aiba; Soo-yong Lee; Lynn Feun; Niramol Savaraj; Macus Tien Kuo
Journal:  Mol Cancer Ther       Date:  2009-12       Impact factor: 6.261

5.  The role of Sp1 in IL-1beta and H. pylori-mediated regulation of H,K-ATPase gene transcription.

Authors:  Arindam Saha; Charles E Hammond; Monika Gooz; Adam J Smolka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

6.  O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter.

Authors:  Ramona Jochmann; Mathias Thurau; Susan Jung; Christian Hofmann; Elisabeth Naschberger; Elisabeth Kremmer; Thomas Harrer; Matthew Miller; Niels Schaft; Michael Stürzl
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

7.  Transforming growth factor-β-inducible early response gene 1 is a novel substrate for atypical protein kinase Cs.

Authors:  Endalkachew A Alemu; Eva Sjøttem; Heidi Outzen; Kenneth B Larsen; Turid Holm; Geir Bjørkøy; Terje Johansen
Journal:  Cell Mol Life Sci       Date:  2010-10-17       Impact factor: 9.261

8.  Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse model.

Authors:  Shih-Chang Shiue; Miao-Zeng Huang; Ting-Fen Tsai; Alice Chien Chang; Kong Bung Choo; Chiu-Jung Huang; Tsung-Sheng Su
Journal:  J Biomed Sci       Date:  2015-01-23       Impact factor: 8.410

9.  Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.

Authors:  Jennifer A McAlpine; Hsin-Tze Lu; Katherine C Wu; Susan K Knowles; James A Thomson
Journal:  BMC Cancer       Date:  2014-08-28       Impact factor: 4.430

10.  The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury.

Authors:  Bing Chang; Lixuan Sang; Ying Wang; Jing Tong; Dai Zhang; Bingyuan Wang
Journal:  BMC Gastroenterol       Date:  2013-10-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.